Post-Menopause: Critical Maintenance Postmenopausal women face the steepest bone loss trajectory while maintaining accelerated muscle loss rates
The present inventors when carried out the reaction of (3-31) amino acid fragment of Semaglutide having the amino acid sequence Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser- Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly with PGi-His(PG)-Aib-OH and further converted the obtained compound to Semaglutide surprisingly found that the said process efficiently controlled the formation of D-His, Des- His, Des-Aib, Di-Aib, Des-Aib-His impurities in the Semaglutide API which is highly advantageous on industrial scale especially for complex peptide molecules like Semaglutide
Example 8 Arg34GLP-1 (9-37) carries out the modification of terminal amino group: 1g Boc-His (Trt) -Aib-OH was dissolved in 10mL dichloromethane and 0.34g p-nitrophenol was added
Semaglutide is a long-acting GLP-1 receptor agonist, structurally optimized from human GLP-1 to extend half-life and enhance stability
The advantage compounds over weeks, resulting in measurable improvements in muscle mass, strength, and body composition
The diluent in the present invention is selected from but not limited to methanol: water, ethanol: water, acetonitrile:water, isopropanol: water and the like
